Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine
J Occup Environ Med
.
2021 Nov 1;63(11):e829.
doi: 10.1097/JOM.0000000000002362.
Authors
Gian Luca Salvagno
1
2
,
Brandon M Henry
3
,
Giuseppe Lippi
4
Affiliations
1
Section of Clinical Biochemistry, University of Verona, Verona, Italy.
2
Sevice of Laboratory Medicine Pederzoli Hspital Peschiera del Garda, Italy.
3
The Heart Institute, Cincinnati Children's Hospital Medical Center Cincinnati, OH.
4
Section of Clinical Biochemistry University of Verona Verona, Italy.
PMID:
34412098
PMCID:
PMC8562910
DOI:
10.1097/JOM.0000000000002362
No abstract available
Publication types
Letter
Comment
MeSH terms
BNT162 Vaccine
COVID-19 Vaccines*
COVID-19*
Humans
Immunoglobulin A
RNA, Messenger
SARS-CoV-2
Substances
COVID-19 Vaccines
Immunoglobulin A
RNA, Messenger
BNT162 Vaccine